Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 830 Cr.
- Current Price ₹ 34.5
- High / Low ₹ 37.0 / 18.5
- Stock P/E 37.7
- Book Value ₹ 6.35
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 15.5 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 52.4% CAGR over last 5 years
- Company's working capital requirements have reduced from 44.3 days to 18.9 days
Cons
- Stock is trading at 5.43 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 55 | 88 | 139 | 148 | 193 | 357 | 461 | 466 | 503 | 668 | |
| 55 | 87 | 135 | 143 | 186 | 346 | 446 | 443 | 464 | 619 | |
| Operating Profit | 1 | 1 | 4 | 5 | 7 | 11 | 15 | 23 | 38 | 49 |
| OPM % | 1% | 1% | 3% | 3% | 4% | 3% | 3% | 5% | 8% | 7% |
| 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | 8 | |
| Interest | 0 | 1 | 2 | 3 | 3 | 3 | 5 | 9 | 16 | 25 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 0 | 1 | 3 | 2 | 4 | 7 | 10 | 15 | 21 | 29 |
| Tax % | 40% | 24% | 28% | 26% | 25% | 26% | 26% | 25% | 25% | 23% |
| 0 | 1 | 2 | 1 | 3 | 5 | 7 | 11 | 16 | 22 | |
| EPS in Rs | 0.07 | 0.16 | 0.25 | 0.13 | 0.28 | 0.54 | 0.29 | 0.47 | 0.66 | 0.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 13% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 52% |
| 3 Years: | 45% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 72% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 14% |
| 3 Years: | 14% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 5 | 10 | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 1 | 4 | 9 | 10 | 13 | 20 | 77 | 88 | 107 | 129 |
| 6 | 10 | 14 | 21 | 30 | 31 | 34 | 107 | 173 | 282 | |
| 11 | 12 | 17 | 18 | 47 | 77 | 97 | 66 | 96 | 159 | |
| Total Liabilities | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | 400 | 594 |
| 0 | 0 | 2 | 6 | 6 | 6 | 20 | 21 | 20 | 94 | |
| CWIP | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 2 | 6 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 17 | 34 | 8 |
| 20 | 31 | 47 | 53 | 93 | 130 | 200 | 245 | 341 | 489 | |
| Total Assets | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | 400 | 594 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2 | -0 | -1 | 1 | 3 | -4 | -29 | 10 | 35 | -3 | |
| -0 | -0 | -4 | -3 | -1 | -2 | -26 | -9 | -20 | -80 | |
| 2 | -1 | 8 | -0 | -2 | 4 | 66 | -12 | -14 | 82 | |
| Net Cash Flow | 0 | -1 | 3 | -2 | -0 | -1 | 11 | -12 | 0 | -0 |
| Free Cash Flow | -2 | -0 | -5 | -4 | 2 | -5 | -43 | 8 | 34 | -52 |
| CFO/OP | -244% | 36% | -2% | 20% | 51% | -18% | -179% | 52% | 98% | 6% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 71 | 68 | 66 | 114 | 75 | 64 | 96 | 116 | 109 |
| Inventory Days | 23 | 28 | 29 | 46 | 49 | 51 | 63 | 73 | 114 | 128 |
| Days Payable | 75 | 49 | 45 | 40 | 90 | 80 | 78 | 52 | 73 | 91 |
| Cash Conversion Cycle | 40 | 51 | 52 | 72 | 73 | 46 | 50 | 117 | 157 | 146 |
| Working Capital Days | 42 | 52 | 27 | 35 | 29 | 27 | 54 | 60 | 54 | 19 |
| ROCE % | 16% | 20% | 12% | 15% | 19% | 15% | 14% | 15% | 15% |
Insights
In beta| Mar 2016 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
||||
| Trade Receivables Turnover Ratio Times |
|||||
| Number of Countries with Export Presence Number |
|||||
| Number of States with Ethical Marketing Reach Number |
|||||
| Number of Approved Products (Domestic & Export) Number |
|||||
| Number of Medical Practitioners Associated Number |
|||||
| Palghar Unit - Daily Output (Single Shift) Litres |
|||||
| Palghar Unit - Oral Liquid Manufacturing Tank Capacity Litres |
|||||
| Ratna Lifesciences - Oncology API Capacity Metric Tonnes p.a. |
|||||
Extracted by Screener AI
Documents
Announcements
-
Reply To The Email Dated 18Th May 2026 Seeking 'Discrepancies In Financial Results'
3h - Audited standalone and consolidated results for half-year and year ended 31 March 2026 submitted on 30 April 2026.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual secretarial compliance report for FY2026 filed; company largely compliant, with USD 20 million FCCBs after period.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 May - The newspaper advertisement for the Postal Ballo Notice dispatched to the shareholders of the Company on 25/May/2026 published in (i) Mumbai Lakshdeep and (ii) Financial …
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
25 May - Postal ballot seeks SME-to-main-board migration on BSE/NSE and director appointments; voting May 26–June 24, 2026.
-
Revision Of Disclosure Made By The Company Under Paragraph 2.1(F) Of The Master Circular Compliance With The Provisions Of The SEBI (LODR) Regulations, 2015 By Listed Entities.
21 May - Plans FCCB issue up to USD 20 million, about Rs 193.69 crore, at 8% coupon.
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals